Abeona Therapeutics Inc vs iShares Global Tech ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while iShares Global Tech ETF trades at $142.15. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Global Tech ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | IXN | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.45 | $149.74 |
52-Week Low | $4.17 | $94.42 |
Enterprise Value | $276.10M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
IXN trades at $142.54, up 2.24% with strong technical momentum as moving averages signal bullish sentiment. The ETF shows robust technical positioning near resistance levels while maintaining neutral oscillator readings. Recent dividend activity and global tech exposure highlight its investment profile.
Outlook remains cautiously optimistic given high valuations and concentration risks in tech holdings. Key opportunities include AI-driven growth exposure, while risks involve stretched valuations and sector volatility. Analyst consensus suggests holding for strategic tech allocation.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →